Pyrazolopyrazine kinase inhibitors

A compound represented by the following structural formula:

• or a pharmaceutically acceptable salt thereof, wherein:
• R1 is —H;
• ring B is pyridyl;
• ring C is represented by a structural formula represented by:
• q is 0 or 1;
• Z is —Y2-Q2;
• Y2 is absent, or C1-10 aliphatic, wherein up to three methylene units of Y2 are optionally and independently replaced with G′ wherein G′ is —O—, —C(O)—, —N(R′)—, or —S(O)p—;
• and Y2 is optionally and independently substituted with one or more Jd;
• Q2 is absent;
• each R′ is independently —H, or C1-C6 alkyl optionally and independently substituted with one or more Ja;
• each Ja is independently halogen, —OR, —N(R)2, —C(O)R, —C(O)OR, —C(O)N(R)2, —NRC(O)R, —NRC(O)OR, —CN, —NO2, or oxo;
• each Jd is independently halogen, —OR, —N(R)2, —C(O)R, —C(O)OR, —C(O)N(R)2, —NRC(O)R, —NRC(O)OR, —CN, or —NO2;
• each R is independently —H or C1-C6 alkyl;
• and
• each p is independently 0, 1, or 2.